Cibus (CBUS) Competitors

In the previous week, Cibus had 6 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 8 mentions for Cibus and 2 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.63 beat Cibus' score of -0.28 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Kyverna Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 264.08%. Cibus has a consensus price target of $9.00, suggesting a potential upside of 420.23%. Given Cibus' higher probable upside, analysts clearly believe Cibus is more favorable than Kyverna Therapeutics.

Cibus has higher revenue and earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Kyverna Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Kyverna Therapeutics' return on equity of -81.92% beat Cibus' return on equity.

Kyverna Therapeutics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market. Comparatively, Cibus has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 33.8% of Cibus shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by company insiders. Comparatively, 29.9% of Cibus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Eliem Therapeutics has lower revenue, but higher earnings than Cibus. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Eliem Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Eliem Therapeutics' return on equity of -47.03% beat Cibus' return on equity.

Cibus has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

33.8% of Cibus shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 29.9% of Cibus shares are held by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cibus presently has a consensus price target of $9.00, suggesting a potential upside of 420.23%. Given Cibus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cibus is more favorable than Eliem Therapeutics.

In the previous week, Cibus had 7 more articles in the media than Eliem Therapeutics. MarketBeat recorded 8 mentions for Cibus and 1 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.00 beat Cibus' score of -0.28 indicating that Eliem Therapeutics is being referred to more favorably in the news media.

33.8% of Cibus shares are owned by institutional investors. 29.9% of Cibus shares are owned by insiders. Comparatively, 31.1% of Evommune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cibus had 7 more articles in the media than Evommune. MarketBeat recorded 8 mentions for Cibus and 1 mentions for Evommune. Evommune's average media sentiment score of 0.00 beat Cibus' score of -0.28 indicating that Evommune is being referred to more favorably in the news media.

Cibus currently has a consensus target price of $9.00, suggesting a potential upside of 420.23%. Evommune has a consensus target price of $43.25, suggesting a potential upside of 217.13%. Given Cibus' higher probable upside, equities research analysts clearly believe Cibus is more favorable than Evommune.

Evommune has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Evommune's return on equity of -62.63% beat Cibus' return on equity.

Evommune has higher revenue and earnings than Cibus. Evommune is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

C4 Therapeutics has a net margin of -289.44% compared to Cibus' net margin of -2,258.89%. C4 Therapeutics' return on equity of -45.45% beat Cibus' return on equity.

C4 Therapeutics has higher revenue and earnings than Cibus. C4 Therapeutics is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

In the previous week, Cibus had 6 more articles in the media than C4 Therapeutics. MarketBeat recorded 8 mentions for Cibus and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.01 beat Cibus' score of -0.28 indicating that C4 Therapeutics is being referred to more favorably in the media.

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 33.8% of Cibus shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by insiders. Comparatively, 29.9% of Cibus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

C4 Therapeutics has a beta of 2.91, suggesting that its stock price is 191% more volatile than the broader market. Comparatively, Cibus has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

C4 Therapeutics currently has a consensus price target of $7.75, indicating a potential upside of 89.02%. Cibus has a consensus price target of $9.00, indicating a potential upside of 420.23%. Given Cibus' higher probable upside, analysts clearly believe Cibus is more favorable than C4 Therapeutics.